Ocular Therapeutix (OCUL) CDO Peter Kaiser Sells 3,035 Shares

What Happened
Peter Kaiser, Chief Development Officer of Ocular Therapeutix (OCUL), sold 3,035 shares of company stock in an open-market transaction on August 24, 2026. The weighted average sale price was $10.77 per share, for total proceeds of approximately $32,687. The sales were made pursuant to an automatic sell-to-cover instruction to satisfy tax withholding on restricted stock units that vested on August 22, 2026, and were not discretionary trades by the reporting person.

Key Details

• Transaction date: August 24, 2026 (Form 4 filed Aug 26, 2026 — appears timely).
• Transaction type/code: Sale (S); proceeds ≈ $32,687.
• Price details: weighted average $10.77; individual sales ranged from $10.6429 to $10.9125. Reporting person can provide per-price breakdown on request (see footnote).
• Reason/footnotes: F1—sell-to-cover under a durable automatic sale instruction (adopted April 9, 2024) to satisfy tax withholding on vested RSUs; not a discretionary trade. F2—weighted-average and price range disclosure. F3—filing notes inclusion of 1,272 shares acquired under the company ESPP on June 30, 2026 (referenced in the filing).
• Shares owned after transaction: not specified in the provided excerpt of the filing.

Context
This was a routine sell-to-cover transaction tied to RSU vesting (a common tax-collection action) rather than a voluntary sell for investment reasons. Such sales are typically administrative and should not be interpreted on their own as a bullish or bearish signal about the insider’s view of the company.